In July Northrop Grumman Corporation (NYSE:NOC) reported that its Next Generation Automated Detection System (NG-ADS) for homeland defense applications has successfully completed a rigorous field test and is ready for the program's next phase.
The NG-ADS technology is a competitor for the Department of Homeland Security's (DHS) upcoming BioWatch Gen-3 Phase II acquisition. The program seeks to deploy a nationwide network of fully autonomous bio-detectors in major metropolitan areas across the United States to provide early warning of a biological attack. DHS recently announced that a request for proposals will be issued later this year.
As a fully automated biological detection system, the NG-ADS continuously collects air samples, analyzes the samples for the presence of multiple biological pathogens, and automatically reports results to public health officials multiple times each day through a secure data network. More than 20,000 samples were collected and analyzed during the recent field test in a variety of indoor and outdoor locations in a major city in the United States .
"There are concerns that our nation won't be ready to respond should a biological attack occur," said Dave Tilles, director of Homeland Security programs at Northrop Grumman's Electronic Systems sector. "Early warning provided by an automated detection system such as the NG-ADS will allow the nation's public health and public safety officials to proactively manage the response to a biological event to reduce exposure and treat the affected population to minimize casualties."
Since the successful field test, additional improvements have been made to the NG-ADS to enhance the system's performance while reducing its life-cycle cost. The proven, life-saving capability of the NG-ADS draws upon Northrop Grumman's decade long experience developing, testing, deploying, and operating bio-detection systems for the U.S. government and other customers.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America 's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. www.PositiveIDCorp.com.
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Read Investorideas.com on Linkedin.com/today
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact: 800 665 0411